Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine

Genetics and Molecular Research

Volumn 13, Issue 2, 2014, Pages 3310-3318

  Zhou, M ^a   Ding, Y J ^a   Feng, Y ^a   Zhang, Q R ^a   Xiang, Y ^a   Wan, H Y ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cytidine deaminase; Genetic polymorphisms; Lung cancer; Xeroderma pigmentosum complementary group D

Indexed keywords

ALANINE; ASPARAGINE; ASPARTIC ACID; CISPLATIN; CYTIDINE DEAMINASE; GEMCITABINE; GLUTAMINE; LYSINE; THREONINE; XERODERMA PIGMENTOSUM GROUP D PROTEIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ADULT; ARTICLE; CANCER GROWTH; CDA GENE; CHINESE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC CORRELATION; GENOTYPE; HETEROZYGOTE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POLYMORPHIC LOCUS; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; TREATMENT OUTCOME; WILD TYPE; XPD GENE; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; GENETICS; PATHOLOGY; PROGNOSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CYTIDINE DEAMINASE; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 84899759185     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2014.April.29.9     Document Type: Article

References (18)

1. Bengala C, Guarneri V, Giovannetti E, Lencioni M, et al. (2005). Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma. Br. J. Cancer 93: 35-40.
2. Booton R, Ward T, Heighway J, Taylor P, et al. (2006). Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer. Cancer 106: 2421-2427.
3. Danesi R, Altavilla G, Giovannetti E and Rosell R (2009). Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors. Pharmacogenomics 10: 69-80.
4. Fukunaga AK, Marsh S, Murry DJ, Hurley TD, et al. (2004). Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway. Pharmacogenomics J. 4: 307-314.
5. Gao WM, Romkes M, Siegfried JM, Luketich JD, et al. (2006). Polymorphisms in DNA repair genes XPD and XRCC1 and p53 mutations in lung carcinomas of never-smokers. Mol. Carcinog. 45: 828-832.
6. Gilbert JA, Salavaggione OE, Ji Y, Pelleymounter LL, et al. (2006). Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin. Cancer Res. 12: 1794-1803.
7. Gurubhagavatula S, Liu G, Park S, Zhou W, et al. (2004). XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J. Clin. Oncol. 22: 2594-2601.
8. Jemal A, Thomas A, Murray T and Thun M (2002). Cancer statistics, 2002. CA Cancer J. Clin. 52: 23-47.
9. Lunn RM, Helzlsouer KJ, Parshad R, Umbach DM, et al. (2000). XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 21: 551-555.
10. Maring JG, Wachters FM, Slijfer M, Maurer JM, et al. (2010). Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. Eur. J. Clin. Pharmacol. 66: 611-617.
11. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, et al. (2001). A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res. 61: 8654-8658.
12. Schiller JH, Harrington D, Belani CP, Langer C, et al. (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346: 92-98.
13. Seker H, Butkiewicz D, Bowman ED, Rusin M, et al. (2001). Functional significance of XPD polymorphic variants: attenuated apoptosis in human lymphoblastoid cells with the XPD 312 Asp/Asp genotype. Cancer Res. 61: 7430-7434.
14. Spitz MR, Wu X, Wang Y, Wang LE, et al. (2001). Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res. 61: 1354-1357.
15. Takenaka T, Yano T, Kiyohara C, Miura N, et al. (2010). Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer 67: 101-107.
16. Tibaldi C, Giovannetti E, Vasile E, Mey V, et al. (2008). Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. 14: 1797-1803.
17. Wei SZ, Zhan P, Shi MQ, Shi Y, et al. (2011). Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med. Oncol. 28: 315-321.
18. Wlodarczyk M and Nowicka G (2012). Common polymorphisms in CYP1A1, GSTM1, GSTT1, GSTP1 and XPD genes and endogenous DNA damage. Mol. Biol. Rep. 39: 5699-5704.